HomeCompareACHFF vs ORCC

ACHFF vs ORCC: Dividend Comparison 2026

ACHFF yields 607.74% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACHFF wins by $286675.49M in total portfolio value
10 years
ACHFF
ACHFF
● Live price
607.74%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$286675.51M
Annual income
$216,573,828,855.55
Full ACHFF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — ACHFF vs ORCC

📍 ACHFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACHFFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACHFF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACHFF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACHFF
Annual income on $10K today (after 15% tax)
$51,657.60/yr
After 10yr DRIP, annual income (after tax)
$184,087,754,527.22/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, ACHFF beats the other by $184,087,754,526.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACHFF + ORCC for your $10,000?

ACHFF: 50%ORCC: 50%
100% ORCC50/50100% ACHFF
Portfolio after 10yr
$143337.77M
Annual income
$108,286,914,428.30/yr
Blended yield
75.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

ACHFF
No analyst data
Altman Z
-2442.7
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACHFF buys
0
ORCC buys
0
No recent congressional trades found for ACHFF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACHFFORCC
Forward yield607.74%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$286675.51M$21.4K
Annual income after 10y$216,573,828,855.55$1.04
Total dividends collected$280839.90M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ACHFF vs ORCC ($10,000, DRIP)

YearACHFF PortfolioACHFF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$71,474$60,773.65$11,190$489.61+$60.3KACHFF
2$482,431$405,954.62$12,229$256.01+$470.2KACHFF
3$3,077,047$2,560,845.28$13,216$130.74+$3.06MACHFF
4$18,557,485$15,265,045.13$14,207$66.02+$18.54MACHFF
5$105,896,296$86,039,786.62$15,234$33.17+$105.88MACHFF
6$572,165,857$458,856,819.94$16,317$16.62+$572.15MACHFF
7$2,929,263,073$2,317,045,606.07$17,468$8.32+$2929.25MACHFF
8$14,220,627,221$11,086,315,733.50$18,695$4.16+$14220.61MACHFF
9$65,515,591,108$50,299,519,981.44$20,006$2.08+$65515.57MACHFF
10$286,675,511,341$216,573,828,855.55$21,407$1.04+$286675.49MACHFF

ACHFF vs ORCC: Complete Analysis 2026

ACHFFStock

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.

Full ACHFF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this ACHFF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACHFF vs SCHDACHFF vs JEPIACHFF vs OACHFF vs KOACHFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.